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Abstract
Background: The existence of a local allergic rhintis was proposed on the basis of the detection of nasal IgE in the
absence of a systemic sensitization. Nevertheless, the significance of this phenomenon remains still unclear.
We assessed the presence of mucosal nasal IgE in patients with ascertained allergic rhinitis, nonallergic rhinitis with
inflammation and in healthy controls.
Methods: Consecutive patients with a well ascertained diagnosis (clinical history, skin prick test, specific IgE assay,
nasal endoscopy, nasal cytology) underwent an immunoenzymatic measurement of specific IgE to grass, cypress,
parietaria and olive in nasal scrapings.
Results: Fifteen patients with allergic rhinitis, 12 with non allergic rhinitis and 14 healthy subjects were studied. The
patients with allergic and nonallergic rhinitis had higher nasal symptoms as compared to control subjects. Systemic
sensitizatition (assessed by skin test and CAP-RAST) was obviously more frequent in allergic rhinitis, than in the
other two groups. Allergen-specific nasal IgE could be detected in all groups (86,7, 33,3, and 50 % positive,
respectively), even more frequently in the control group than in nonallergic rhinitis patients. No difference among
allergens was identified. Out of the 26 non-allergic patients (non allergic rhinitis + controls) nasal IgE were positive
in 11(42 %).
Discussion: According to the results, the presence of nasal IgE against allergens seems to be a non-specific
phenomenon, since they can be detected also in non allergic rhinitis and in healthy subjects.
Conclusion: It can be hypothesized that the nasal IgE production represents a form of spontaneous immune
response.
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Background
Rhinitis is defined as an inflammation of the nasal mu-
cosa, usually characterized by rhinorrhoea, sneezing,
nasal blockage and itching, variably associated. Those
symptoms can be accompanied, expecially in the allergic
form, by ocular symptoms such as lacrimation, eye itch-
ing, conjunctival hyperemia [1]. Allergic rhinitis (AR) is
the most common form of non-infectious rhinitis, and it
is triggered by an IgE-mediated immune response to
allergens. Its prevalence reaches about 35 % [2] within
the general population, and continues to increase [3].
Also non-allergic conditions can cause symptoms of
rhinitis: infections, hormonal imbalance, physical/irritant
agents, anatomical abnormalities or drugs [4]. Also the
non-allergic form of rhinitis (NAR) are of clinical rele-
vance. These are characterized essentially by an intense
inflammatory infiltration, in the absence of a systemic
IgE-sensitization. According to the predominant cell
types, NAR can be distinguished into NARES (non-aller-
gic rhinitis with eosinophils), NARMA (non-allergic
rhinitis with mast cells), NARNE (non-allergic rhinitis
with neutrophils) and NARESMA (non-allergic rhinitis
with eosinophils and mast cells) [5–8].
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Since 1975, another pathophysiological type of rhinitis
was proposed, characterized by the presence of allergen-
specific IgE only in the nose, without any evidence of
systemic sensitisation detectable by skin prick test (SPT)
or specific IgE serum assays (CAP-RAST) [9]. This ob-
servation suggested the term of “entopy”[10] and, subse-
quently, of “local allergic rhinitis” (LAR) [11]. These
definitions are still a matter of debate, since LAR has
not been yet clearly identified as an independent noso-
graphic entity. With the aim of exploring more in depth
the local aspects of IgE response, we evaluated the pres-
ence of nasal IgE, in two groups of patients with well
identified forms of rhinitis, and in healthy controls.
Methods
Adult patients were assessed for the presence of allergen-
specific nasal IgE, after the type of rhinitis was classified in
detail according to the diagnostic procedure. Patients were
subdivided into AR (positive SPT and CAP-RAST), and
NAR (negative SPT and CAP-RAST, with nasal inflamma-
tion). A control group of healthy subjects (no rhinitis
symptoms and negative SPT/CAP-RAST) was also in-
cluded for comparison. The study took place between
November 2014 and January 2015 at the Rhinology Unit
of the University of Bari. All subjects provided an in-
formed consent for the management of their anonymous
clinical data. The inner ethical committee was simply noti-
fied, since this was not an interventional study, no placebo
was used, and the procedures were part of the standard
diagnostic practice. According to the existing laws, also
the healthy volunteers could be admitted, after written in-
formed consent. The diagnostic work-up for rhinitis in-
volved: personal clinical history, family history, symptoms
(scores and visual analog scale), SPT, CAP-RAST assay,
nasal endoscopy, nasal scraping for cytology, and assay for
nasal mucosal IgE (see below). Those patients with symp-
toms of chronic rhinosinusitis, anatomical abnormalities
(septal deviation, turbinate hyperthrophy), unilateral
symptoms/signs or malignancies were excluded from the
assessment of nasal IgE. We also excluded those patients
reporting symptoms of possible acute infectious diseases
(e.g. common cold) in the last month. All patients were
medication-free (local/systemic antihistamines, local/sys-
temic corticosteroids) in the past 2 weeks.
Clinical assessment
Obstruction and itching were assessed by a 10-cm visual
analog scale (0 = totally obstructed to 10 = absent; 0 = ab-
sent to 10 = intense, respectively) [12]. Rhinorrhea and
sneezing were simply assessed as present/absent. Positive
family history was defined as the presence of rhinitis
and/or asthma in at least one parent.
Skin prick test
It was performed using a panel of the most common
aeroallergens (Stallergenes, Milan, Italy) according to the
recommendations of the European Academy of Allergy
and Clinical Immunology: house dust mite, grass mix,
Parietaria, olive, cypress, mugwort, alternaria, ragweed,
cat and dog dander [13].
Serum IgE assay (CAP-RAST)
Allergen-specific IgE antibodies against the same allergens
assayed with skin test were measured by a quantitative im-
munoassay (Immunocap® Thermo Fisher Scientific Inc.
Uppsala, Sweden). The measure range of the test varies
from 0.1 to 100 kU/L, and in clinical practice, 0.35 kU/L is
commonly used as a the optimal lower cut-off.
Nasal endoscopy
It was carried out by a 3,4 mm diameter flexibile-fibroscope
(Vision-Sciences® ENT-2000), to assess the presence of
major abnormalities, such as septal deviation, polyposis,
turbinate hypertrophy, or exudation from the ostiomeatal
complex.
Nasal cytology
This procedure was performed by scraping the middle
part of the inferior turbinate with a Rhino-Probe® device
(Arlington Scientific). The sample was smeared on a
slide, air-dried, then stained with the May-Grünwald
Giemsa preparation. The type and cell number were ex-
amined using microscopy (Nikon® E600). Cell types were
identified, and intracellular components were studied at
x1000 in oil immersion. The mean number per 50 fields
was calculated and reported [14, 15]. This noninvasive
method allows to obtain representative samples of the
nasal mucosa and its cellular components [16].
Nasal IgE
Samples for nasal IgE assay were collected by Rhino-
probe® scraping, as for nasal cytology. Samples were di-
luted in 0.5 mL physiological solution, then stored at 4 °C.
Measurement of nasal specific IgE was carried out by the
Immunocap® Specific IgE tests (Thermo Fisher Scientific
Inc, Uppsala, Sweden) by a quantitative immunoassay.
The test is the same routinely used on serum or plasma
samples. In order to establish a lower threshold limit of
detection we tested 10 negative controls (healthy, negative
SPT and CAP-RAST), and the limit resulted to be 0.17
kU/L. Specific IgE to parietaria, olive, dust mite, cypress
and grasses were assayed.
Statistical analysis
Demographic and clinical characteristics were analyzed
by descriptive statistics (% or mean and SD). Continuous
variables were analyzed by the t test for independent
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samples, whereas the Chi-square test was used for quali-
tative measures. The 3 groups were compared by the
ANOVA test. P values for the null hypothesis was set at
0.05. The dedicated software SPSS22 was employed.
Results
Fourty-one patients (19 male, mean age 36.2 ± 16.3 years)
were studied between November 2014 and January 2015.
All the subjects were consecutively enrolled for the nasal
IgE assay, once a diagnosis was made on the basis of the
procedures mentioned before. The studied population
was subdivided into: AR (n = 15), NAR (n = 12) and con-
trols (n = 14). These latter included volunteers enrolled
among healthcare professionals, postgraduate students
or nurses. The 3 groups were homogeneous for demo-
graphic characteristics as summarized in Table 1. Unex-
pectedly, a positive family history for atopy was more
frequent in the NAR group. Those patients with AR or
NAR had significantly more severe rhinorrhea, itching,
sneezing and obstruction versus the control subjects
(Fig. 1). As per inclusion criteria, only AR patients had
positive IgE assay and SPT, as detailed in Table 1. The
distribution of serum and SPT positivities for each aller-
gen was consistent (Table 2), although the positivity for
nasal IgE was, on average, lower with respect to the
standard diagnostics. In particular, the serum IgE assay
provided more frequently positive results, although the
difference among groups was not significant. The mean
values of nasal IgE (irrespectively of the allergen) in AR,
NAR and controls were 1.03 ± 0.84, 0.79 ± 0.90 and 0.67
± 0.45 kU/L, respectively. Looking more in depth to
nasal IgE, (cypress, olive, dust mite, parietaria, grass),
there was no significant difference in the number of pa-
tients proving positive among AR, NAR and controls
(86, 33.3, and 57.1 %, respectively), but the control group
had an overall higher rate of local IgE positivity versus
the NAR group, although this difference was not statisti-
cally significant (Fig. 2). More in detail, it appeared that
in the AR group there was a higher occurrence of posi-
tivities vs NAR and controls for cypress (26,7 % vs 8,3 %
vs 7,1 %), olive (20 % vs 16.7 % vs 7.1 %), and grass
(40 % vs 16.7 % vs 21.4 %). Local nasal IgE to Parietaria
were detected more frequently in the AR patients than
in NAR and controls (73.3 % vs 25 % vs 42.9 %; p = 0.04)
(Fig. 2). Among non allergic patients (NAR + controls,
N = 26) nasal IgE were detectable for parietaria (67.9 %),
olive (26.8 %,), cypress (15.4 %), dust mite (60.7 %) and
grasses (38.1 %). There was no significant difference
concerning each single allergen, except for Parietaria,
more frequently positive in AR patients. As expected,
there was a significant difference in the differential cell
count at nasal cytology between the patients with and
without rhinitis. This was true for each cell type
(Table 3). No difference in the percentage of degranulat-
ing mast cells was found between AR and NAR patients.
Discussion
In general, more than 60 % of patients with NAR receive a
generic diagnosis of “idiopathic” rhinitis, that is based on
an exclusion criterion [8]. Although the pathophysiology








Age, mean ± SD 37.6 ± 16.3 32.4 ± 15.2 37.8 ± 17.7 0650
Sex (M/F) 8/6 4/8 10/5 0214
ASTHMA n (%) 1 (7.1) 2 (16.7) 3 (21) 0.1
Family history, n (%) 0 4 (33.3) 1 (7.1) 0028
ASA sensitivity, n 0 0 0 1,0
SPT positive, n (%) 0 0 15 (100) 0.001
Grass 0 0 3 (20)
Parietaria 0 0 2 (13)
Olive 0 0 4 (26)
Cypress 0 0 6 (40)
Dust mite 0 0 5 (33)
CAP-RAST positive n(%) 0 0 15 (100) 0.001
Grass 0 0 6 (40)
Parietaria 0 0 8 (54)
Olive 0 0 7 (47)
Cypress 0 0 10 (67)
Dust mite 0 0 8 (54)
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of those forms of rhinitis remains poorly defined, an infil-
tration of eosinophils, mast-cells and T-lymphoctyes can
be frequently evidenced, this supporting the presence of
an active inflammation. Based on this, the hypothesis of a
“local” allergic reaction has been suggested.
In 1975 Huggings demonstrated, in a qualitative way, the
presence of house dust mite-specific IgE in the nose of sub-
jects with symptoms of rhinitis but no evidence of systemic
IgE [9], whereas in 2003 Powe introduced the concept of
“entopy” [10]. He assessed 32 patients [11 with AR, 10 with
idiopathic rhinitis and 12 controls), and found nasal grass-
specific IgE in 3 of the patients with idiopathic rhinitis.
Thus the term entopy was used to indicate an allergy con-
fined to the nasal mucosa, in the absence of the evidence of
systemic sensitization. Subsequently, in 2004, the strict im-
munological interaction between T lymphocytes and mast
cells in entopy were described [17, 18]. Other authors,
evaluating relatively large groups of patients, introduced the
term of “local allergic rhinitis” (LAR), to describe the iso-
lated presence of specific IgE in the nasal mucosa. In this
regard, the specific nasal provocation test was used to diag-
nose the disease [11, 19].
Our results confirmed the presence of nasal IgE in AR
subjects, usually in agreement with the systemic
sensitization profile, revealed by IgE serum assay and
SPT. Interestingly, nasal specific IgE could be detected
also in a relevant percentage of patients with NAR. More
importantly, as unexpected finding, nasal allergen-
specific IgE could be found also in 50 % of the healthy
control subjects. Although the number of patients stud-
ied is small, the percentage remains highly significant.
This latter aspect would suggest, as an hypothesis, that a
local secretion of IgE could be part of a spontaneous im-
mune response to environmental agents. The identifica-
tion of nasal allergen-specific IgE also in healthy subjects
and in patients with non allergic rhinitis suggest that the
concept of LAR should be reconsidered and re-evaluated.
These observations also suggest that a more detailed diag-
nostic approach, involving nasal endoscopy and nasal
cytology, should be carried out when the diagnosis is un-
certain. In fact, nasal cytology can better define and refine
the details of nasal inflammation. The technique is not
Fig. 1 Panel a (left): % of patients reporting symptoms of sneezing and rhinorrhea. Panel b (right) visual analog scale score for obstruction and
itching (mean and SD). Significant p values are reported above the bars
Table 2 N and % of positive patients to SPT, CAP-RAST and
nasal IgE assay in AR patients (N = 15)
SPT+ CAP-RAST+ Nasal IgE+
Cypress 6 (40) 10 (67) 4 (27)
Olive 4(26) 7(47) 3 (20)
Dust Mite 5 (33) 8 (53) 5 (33)
Parietaria 2 (13) 8 (53) 11 (73)
Grass 3 (20) 6(40) 6 (40)
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invasive, does not alter the cellular profile and it is also used
in electron microscopy studies for other diseaes [16, 20].
According to this, in the presence of symptoms of rhinitis,
without a clear evidence of an allergic sensitization, the de-
tection of mucosal nasal IgE should not be considered as a
certain demonstration of LAR. In addition, NAR cannot be
immediately defined as LAR, even in the presence of local
IgE, because of both severity, cytological pattern and, pos-
sibly, the association with polyposis [21]. It can be argued
that the aforementioned studies on LAR suffered from a
relatively low specificity. The allergen nasal provocation test
implies the administration of allergens at high concentra-
tion, that can provoke a non specific response expecially in
NAR where the nasal mucosa is already inflamed [22]. Also,
acoustic rhinometry is now considered poorly reproducible
and difficult to standardize [23]. In this regard, the active
anterior rhinomanometry after decongestion would be pref-
erable from a functional point of view [24, 25]. To better
define the pathophysiological picture, an incremental-
concentration nasal specific challenge with each allergen
should be performed in NAR and controls, but this was not
part of the aims of the present work.
Indeed, the postivity of allergen-specific nasal IgE in the
absence of a detectable systemic sensitization remains un-
clear, needs more experimental proof [26, 27], and is any-
way not explained by this experimental study. In fact the
main limitation of the present study is the absence of spe-
cific nasal provocation tests. On the other hand, the pres-
ence of nasal allergen specific IgE in heathy subjects
(without symptoms, but exposed to allergens) would not
justify the use of a challenge. We can only hypothesize
that the nasal mucosa, exposed since birth to allergens,
can evoke an IgE synthesis in the context of the immune
response, independently of the atopic sensitization [28].
This is indirectly confirmed by the fact that in allergic
patients the presence of local nasal and systemic IgE to
allergens are consistent, expecially for perennial allergens
(parietaria 34,6 % and mites 26 %. Finally, to date there is
no formal evidence that LAR can evolve into an AR with a
systemic IgE production [29].
Fig. 2 % of patients with positive assay for nasal IgE, in total and for each single allergen. A significant difference among the 3 groups was
detected only for Parietaria. Significant p values are reported above the bars
Table 3 Results of nasal cytology in the three studied groups
HEALTHY CONTROLS
(n = 14)
NONALLERGIC RHINITIS (n = 12) ALLERGIC RHINITIS (n = 15) P value a
Neutrophils 23,5 ± 5,8 303,4 ± 19,3 502,5 ± 24,4 <0.001
Eosinophils 0 82,5 ± 10,4 59,4 ± 7,9 <0.001
Lymphocytes 7,3 ± 2,3 8,7 ± 3,9 34,5 ± 5,9 <0.001
Mast cells 0 28,5 ± 6,3 10,3 ± 3,7 <0.001
aAllergic Rhinitis vs the other groups (Non Allergic Rhinitis and Controls)
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Conclusion
The detectable presence of allergen-specific IgE on the
nasal mucosa of subjects with nonallergic rhinitis and
healthy subjects suggests that this phenomenon could be







All the clinical and laboratory data are available, on request, at
gelardim@inwind.it in the respect of patients’ anonimity.
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